title: [Study on polymorphic Hind III restriction site of the Y chromosome and essential hypertension in Tangshan district].
abstract: OBJECTIVE
  Since males are at higher risk of cardiovascular diseases than females, the aim of the study was to examine whether there is an association between BP and a polymorphic Hind III biallelic marker in nonrecombining region of Y chromosome in essential hypertension in Tangshan district in China.
  
  
  METHODS
  In the study, 225 patients with essential hypertension and 187 healthy people were enrolled into this study as control group. DNA was extracted from white blood cell. Segments of polymorphic Hind III restriction site of the Y chromosome were amplified from DNA by polymerase chain reaction (PCR). PCR products were restricted with 10 U of Hind III for a night at 37 degrees C. The digested products were subjected to electrophoresis in 3% agarose gels, and stained with ethidium bromide.
  
  
  RESULTS
  We amplified 178 controls (95.2%) and 216 essential hypertensive patients (96.0%) successfully. Hind III(-) genotype was found in 45.8% of the men in essential hypertension and in 32.0% of the men in the controlled group. The Hind III(-) genotype was significantly higher than that in the controls (chi2 = 7.782, P = 0.007). However, the Hind III(+) genotype was lower in SBP (133.16 mm Hg +/- 21.60 mm Hg vs. 143.58 mm Hg +/- 24.16 mm Hg, P < 0.001), DBP (82.82 mm Hg +/- 11.72 mm Hg vs. 86.82 mm Hg +/- 12.65 mm Hg, P = 0.001), pulse pressure (50.34 mm Hg +/- 14.31 mm Hg vs. 56.76 mm Hg +/- 14.20 mm Hg, P < 0.001) and mean arterial pressure (99.59 mm Hg +/- 14.19 mm Hg vs. 105.74 mm Hg +/- 15.31 mm Hg, P < 0.001) than the Hind III(-) genotype.
  
  
  CONCLUSIONS
  Polymorphic Hind III restriction site of the Y chromosome seemed to be associated with essential hypertension in Tangshan district in China.
authors.affiliation: Beijing Anzhen Hospital, Capital Medical University & Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China.
authors.forename: Qing-xiang
authors.initials: QX
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Yuan
authors.forename: Shou-ling
authors.initials: SL
authors.lastname: Wu
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Ci
authors.forename: Nan
authors.initials: N
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Hao
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Zhu
authors.forename: Hong-fen
authors.initials: HF
authors.lastname: Li
authors.forename: Hong-bing
authors.initials: HB
authors.lastname: Yan
authors.forename: Zuo
authors.initials: Z
authors.lastname: Chen
authors.forename: Guo-zhang
authors.initials: GZ
authors.lastname: Liu
mesh_terms: D016022:Case-Control Studies; D002681:China; D041322:Chromosomes, Human, Y / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D006801:Humans; D006973:Hypertension / Q000235:genetics*; D008297:Male; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D015265:Site-Specific DNA-Methyltransferase (Adenine-Specific) / Q000378:metabolism
chemical_list: C090528:DNA modification methylase HindIII; D015265:Site-Specific DNA-Methyltransferase (Adenine-Specific)